Abstract
Phase 3 trials show the RVD (lenalidomide, bortezomib, and dexamethasone) triplet to be superior to RD (lenalidomide/dexamethasone) for initial therapy of myeloma. However, among older transplant-ineligible patients [pts], RVD has not been directly compared with doublets (RD or VD[bortezomib/dexamethasone]), nor has RD been compared with VD, leaving an important gap in evidence. We used population-based data to compare these regimens among older patients (Medicare beneficiaries) with receiving first-line therapy for myeloma.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call